


China's WuXi Biologics to increase manufacturing capacity in Germany

June 2, 2023 | News

In response to global clients' increasing demand for contract manufacturing services



China-headquartered WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organisation (CRDMO), has announced that it will increase manufacturing capacity in Germany.

Since 2020, WuXi Bio has significantly invested in the purchase, construction and adaptations of two state-of-the-art manufacturing facilities in Germany, enabling the company to offer end-to-end services spanning the entire biologics manufacturing process. The sterile filling and freeze-drying plant at Chempark Leverkusen, with an annual capacity of approximately ten million doses, is being expanded to include a second variable filling line. The state-of-the-art drug substance facility in Wuppertal is expected to double its total capacity from 12,000L to 24,000L on 30,000 square metres.

Together with the drug product facility in Leverkusen, the expanded drug substance facility in Wuppertal will further enhance WuXi Bio's clinical and commercial manufacturing capacities in Europe. This expansion will strengthen WuXi Bio's global dual-sourcing network strategy, which ensures that materials can be sourced and products manufactured at multiple sites within the company's network.

WuXi Biologics Germany GmbH currently employs a growing team of more than 360 highly skilled people at both sites in Leverkusen and Wuppertal.